Cipher Pharmaceuticals, Inc. (OTC:CPHRF)

CIPHER PHARMACEUTICALS INC (OTC:CPHRF) (CPH.TO) ($11.08; $267.3 market cap) announced Q3 2024 results:

• Sales of $10.4 million vs $6.1 million in the prior year and in line with analyst estimates of $10.3
• Non-GAAP EPS of $0.07 vs $0.12 in the prior year and below analyst estimates of $0.14

"Since my transition to Chief Financial Officer during the third quarter, I have dedicated a large portion of my time executing an efficient financial structuring of our Natroba Acquisition, managing our new bank financing relationship, and supporting the financial and administrative integration of the Natroba business into the existing Cipher infrastructure. I look forward to continuing to progress these activities, while also driving other efficiencies in the business."

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne

CIPHER PHARMACEUTICALS INC (OTC:CPHRF) (CPH:TO) operates as a specialty pharmaceutical company in Canada. The company reported its fourth quarter 2023 results: (figures in USD)

• Sales of $4.9 million vs $4.9 million in the prior year 

• EPS of $0.15. vs $0.12 in the prior year 

"Cipher's priorities continue to be focused on profitability and capital allocation strategies that benefit our shareholders. We had several position catalysts in 2023, including a highly successful substantial issuer bid, as well as secured a credit facility with the Royal Bank of Canada at favorable terms to the present day market. We continue to work diligently for our shareholders and we are excited to execute on our growth strategy in 2024 and beyond."

We will be digging into the details of the quarter over the weekend.

CIPHER PHARMACEUTICALS INC (OTC:CPHRF) (CPH:TO) ($2.91USD; $3.97CAD), a company that operates as a specialty pharmaceutical company in Canada, announced it intends to buy up to $6 million worth of shares for cancellation at a price between CAD $3.95 and $4.75 per share ($2.89 to $3.48 USD)

“The Board of Directors of Cipher (the "Board") believes that the SIB is in the best interests of our Shareholders and the Company given, among other things, its significant level of interest generating cash on hand, and future access to financing with a $35 million revolving credit facility, both expected to drive the Company's future growth plans. Considering the Company's broad product pipeline and the present day market opportunities for acquisitions, the Board and the Company's management believe the current market price of the Common Shares does not currently reflect the fundamental value of the Company. The Company intends to fund the SIB with a portion of its reported cash on hand of US$36.3 million as of June 30, 2023.”

In November 2022, we published an article that delves further into Cipher’s history, product pipeline, caveat considerations, and a healthy look at industry peers from which we can derive some reasonable valuation expectations for the company's stock.

CIPHER PHARMACEUTICALS INC (OTC:CPHRF) (CPH.TO) operates as a specialty pharmaceutical company in Canada. The company reported its first quarter 2023 results: (figures in USD)

• Sales of $4.9 million vs $5.4 million in the prior year 
• EPS of $0.10. vs $0.08 in the prior year 

“Cipher’s efficient business model enabled us to deliver strong operating results in the first quarter, with our robust product portfolio generating substantial cash flow from operations. During the quarter, Cipher achieved a 54% net income margin and delivered 25% year-over-year growth in EPS, while adding $4.6 million of cash to our balance sheet. With a strong balance sheet, and a substantial credit facility at our disposal, we are in an ideal position to drive our next phase of growth.”